Highest-materiality recent filing
Supernus Q1 revenue $207.7M (+39% YoY); growth products up 56%; reaffirms FY2026 guidance
Total revenues $207.7M, up 39% YoY; combined growth product revenues $149.1M (+56%).
Supernus acquires NV-5138/SPN-820 assets from Navitor; up to $350M in milestones
Supernus buys all IP, inventory, and regulatory materials for CNS compound NV-5138 (SPN-820).
Supernus Q4 revenue $211.6M (+21% YoY), FY revenue $719M (+9%); FY26 guidance $840-870M
Record Q4 total revenue $211.6M (+21% YoY); full year $719.0M (+9% YoY).
Supernus Q3 rev $192M, up 9%; growth products up 52%; ONAPGO supply constraint
Total revenues $192.1M (+9% YoY); combined growth product sales $149.2M (+52%).
Supernus closes Sage acquisition for $8.50/share + CVRs; pro forma shows $118M H1 loss
Acquisition closed July 31, 2025; Supernus paid $8.50 per share cash plus CVRs up to $3.50 per share.
Supernus Q2 2025: Qelbree +31%, Sage acquisition closed, guidance raised
Total revenues Q2 2025: $165.5M vs $168.3M; non-GAAP rev ex-Trokendi/Oxtellar up 17% YoY.
Supernus closes Sage acquisition for $8.50/share + up to $3.50 CVR; ~$561M cash, accretive in 2026
Total cash consideration ~$561M; 36.3M shares (58%) tendered; merger closed July 31, Sage wholly owned.
Supernus acquires Sage Therapeutics for up to $795M ($12/share including CVR)
Supernus to acquire Sage via tender offer at $8.50/share cash plus CVR up to $3.50/share, total up to $795M.
Supernus receives Paragraph IV ANDA filings for Qelbree; patents expire 2029-2035
Received Paragraph IV notice letters for ANDA of viloxazine ER capsules 100, 150, 200 mg.
Supernus Q1 2025: Qelbree sales +44% to $64.7M; ONAPGO launched; total revenue +4% to $149.8M
First quarter 2025 total revenue $149.8M, up 4% YoY; operating loss $(10.3)M vs $(3.2)M in prior year.
Supernus FY 2024 rev $661.8M; Qelbree +72%; ONAPGO approved; SPN-820 Phase 2b fails
Full year 2024 revenue $661.8M (+9% YoY); Qelbree net sales $241.3M (+72%) and GOCOVRI $130.8M (+9%).
Supernus SPN-820 Phase 2b misses primary endpoint in treatment-resistant depression
SPN-820 showed MADRS score change of -12.3 vs placebo -11.9 at Week 4; p=not significant.
ONAPGO approved for continuous treatment of motor fluctuations in advanced Parkinson's patients not controlled by oral levodopa.
Supernus announces FDA label update for Qelbree with new pharmacodynamic and lactation data
FDA approved updated Qelbree label including serotonin 5-HT2C partial agonist activity and norepinephrine transporter inhibition data.
Supernus Q3 revenue $175.7M (+14% YoY); raises FY guidance; Qelbree sales +68%
Net sales of Qelbree $62.4M (+68% YoY); GOCOVRI $35.6M (+8% YoY) in Q3 2024.
Supernus SPN-820 Phase 2a shows rapid antidepressant response: 50% MADRS rate at 4 hours
SPN-820 achieved 50.0% MADRS response rate and 35.0% remission rate at 4 hours post-dose in open-label Phase 2a study.
Supernus SPN-820 Phase 2a data: rapid depressive symptom reduction with favorable tolerability
HAM-D6 score improved -6.1 at 2 hours, -9.6 at Day 10; MADRS improved -16.6 at 4 hours, -22.9 at Day 10.
Supernus announces FDA accepted resubmission of SPN-830 NDA; PDUFA date Feb 1, 2025
FDA acknowledged resubmission of NDA for SPN-830 (apomorphine infusion device) for continuous treatment of motor fluctuations in Parkinson's disease.
Supernus Q2 revenues up 24% to $168.3M; Qelbree sales surge 92%; raises FY2024 guidance
Total Q2 revenues $168.3M (+24% YoY); Qelbree net sales $59.4M (+92% YoY); GOCOVRI $31.7M (+10% YoY)
Supernus resubmits NDA for SPN-830 apomorphine infusion for Parkinson's OFF episodes
Resubmitted NDA for SPN-830 (apomorphine infusion device) to FDA for continuous treatment of OFF episodes in Parkinson's disease.
Supernus reports positive interim Phase 2a data for SPN-817 in treatment-resistant seizures
75% median focal seizure reduction at 3-4 mg BID in maintenance period; 86% reduction in open-label extension.
Supernus to present interim Phase IIa data for SPN-817 on May 23
Interim data from open-label Phase IIa study of SPN-817 for treatment-resistant seizures to be reviewed at webcast on May 23, 2024.
Supernus Q1: Qelbree sales +75% to $45.1M; SPN-830 gets FDA CRL; FY guidance reiterated
Total revenue of $143.6M; Qelbree net sales surged 75% YoY to $45.1M (IQVIA Rx +31%).
Supernus receives FDA Complete Response Letter for SPN-830 (apomorphine infusion device)
FDA issued CRL stating NDA for SPN-830 (apomorphine infusion) not ready for approval.
On April 22, 2024, John M. Siebert, Ph.D. informed Supernus Pharmaceuticals, Inc. (the “Company”) that he has decided to retire from the Company's Board of Directors (the "Board"), effective at the Company's Annual Meeting of Stockholders in June 2024
Max materiality 0.90 · Median 0.60 · Most common event other_material